Brief: Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers
08/06/2026 12:06
BRIEF-Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers June 8 (Reuters) - Seaport Therapeutics Inc SPTX.O:
SEAPORT THERAPEUTICS REPORTS POSITIVE MULTIPLE-ASCENDING DOSE DATA FROM PHASE 1 PROOF-OF-CONCEPT TRIAL OF GLYPHAGO™ IN HEALTHY VOLUNTEERS
SEAPORT THERAPEUTICS - REPEAT DOSING OF GLYPHAGO SHOWS FAVORABLE SAFETY AND NO LIVER-RELATED ADVERSE EVENTS
SEAPORT THERAPEUTICS - SEVEN-DAY GLYPHAGO DOSING ACHIEVES THERAPEUTIC AGOMELATINE EXPOSURES WITHOUT LIVER ENZYME ELEVATIONS
SEAPORT THERAPEUTICS - TO INITIATE PHASE 2A GLYPHAGO TRIAL IN SECOND HALF OF 2026
SEAPORT THERAPEUTICS - TO INITIATE PHASE 2B GLYPHAGO TRIAL IN FIRST HALF OF 2027
Source text: ID:nBw3W9JFFa
Further company coverage: SPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seaport Therapeutics
See all newsBrief: PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo
Brief: Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers
Biotech firm Odyssey raises $279 million in upsized US IPO (updated)